Emmaus Life Sciences(EMMA)
TORRANCE, CABiotechnology
Focus: Emmaus Life Sciences is a public biotech company focused on rare and metabolic diseases, with a single FDA-approved oral amino acid therapy (ENDARI/L-glutamine) for sickle cell disease generating all revenue.
Profile data last refreshed 8h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Emmaus Life Sciences
AI assessmentNot HiringNo open roles listed right now. Follow Emmaus Life Sciences to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Emmaus Life Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$17M
FY2025
Key Products
$8M Part DDeclining
Peak
Flagship orphan drug and sole revenue driver; peak-stage product facing generic erosion (L-glutamine ANDA post-LOE) and competitive pressure in SCD market.
Help build intelligence for Emmaus Life Sciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.